Nausea and vomiting caused by chemotherapy. Nausea and vomiting
Conditions
Interventions
Intervention 1: Intervention group 1: They will receive a standard anti-nausea regimen including: 8 mg of intravenous dexamethasone, along with 1 mg of granistrone and aperitnet 125 minutes before che
Sponsors
Jahrom University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients over 18 years of age with pathologically or cytologically confirmed malignancy Patients undergoing emtogenic chemotherapy including carboplatin, irinotecan, cyclophosphamide Serum creatinine =2.0 mg/dl. Written informed consent
Exclusion criteria
Exclusion criteria: being pregnant Suffering from cognitive diseases and neurological diseases Treatment with another psychiatric medication such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days before or during protocol treatment Simultaneous abdominal radiotherapy Simultaneous use of quinolone antibiotic treatment Chronic alcoholism Hypersensitivity to olanzapine Known heart disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response to treatment as defined by the absence of nausea and vomiting or the need to receive adjuvant medication. Timepoint: Starting on the first day of treatment with olanzapine (day-2) and daily until day 5. Method of measurement: Using the Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of nausea. Timepoint: Starting on the first day of treatment with olanzapine (day-2) and daily until day 5. Method of measurement: According to the length of time the person has been nauseous.;Number of vomiting. Timepoint: Starting on the first day of treatment with olanzapine (day-2) and daily until day 5. Method of measurement: According to the number of times the person has vomited. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNavid Kalani
Jahrom University of Medical Sciences
Outcome results
None listed